Rouse B, Azen C, Koch R, et al. Maternal phenylketonuria collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. Am J Med Genet 1997;69:89-95. View abstract.

Sturtevant FM. Use of aspartame in pregnancy. Int J Fertil 1985;30:85-7. View abstract.

Silkaitis RP, Mosnaim AD. Pathways linking L-phenylalanine and 2-phenylethylamine with p-tyramine in rabbit brain. Brain Res 1976;114:105-15. View abstract.

PKU - Dietary Treatment of the Untreated Adult PKU. National Society for Phenylketonuria (NSPKU). 1996-2001. Available at: web.ukonline.co.uk/nspku/untreatd.htm

Lehmann WD, Theobald N, Fischer R, Heinrich HC. Stereospecificity of phenylalanine plasma kinetics and hydroxylation in man following oral application of a stable isotope-labelled pseudo-racemic mixture of L- and D-phenylalanine. Clin Chim Acta 1983;128:181-98. View abstract.

Zhao G. [Inherited metabolic aberration of phenylalanine in the family members of patients with essential hypertension and stroke]. Chung Hua I Hsueh Tsa Chih (Taipei) 1991;71:28, 388-90. View abstract.

Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-9.

Heller B, Fischer BE, Martin R. Therapeutic action of D-phenylalanine in Parkinson's disease. Arzneimittelforschung 1976;26:577-9. View abstract.

Kitade T, Odahara Y, Shinohara S, et al. Studies on the enhanced effect of acupuncture analgesia and acupuncture anesthesia by D-phenylalanine (2nd report)- schedule of administration and clinical effects in low back pain and tooth extraction. Acupunct Electrother Res 1990;15:121-35. View abstract.

Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology 1997;16:136-46. View abstract.

Gardos G, Cole JO, Matthews JD, et al. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia. Neuropsychopharmacology 1992;6:241-7. View abstract.

Walsh NE, Ramamurthy S, Schoenfeld L, Hoffman J. Analgesic effectiveness of D-phenylalanine in chronic pain patients. Arch Phys Med Rehabil 1986;67:436-9. View abstract.

Mitchell MJ, Daines GE, Thomas BL. Effect of L-tryptophan and phenylalanine on burning pain threshold. Phys Ther 1987;67:203-5. View abstract.

Antoniou C, Schulpis H, Michas T, et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol 1989;28:545-7. View abstract.

Siddiqui AH, Stolk LM, Bhaggoe R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology 1994;88:215-8. View abstract.

Thiele B, Steigleder GK. [Repigmentation treatment of vitiligo with L-phenylalanine and UVA irradiation]. Z Hautkr 1987;62:519-23. View abstract.

Cormane RH, Siddiqui AH, Westerhof W, Schutgens RB. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res 1985;277:126-30. View abstract.

Kuiters GR, et al. Oral phenylalanine loading and sunlight as source of UVA irradiation in vitiligo on the Caribbean island of Curacao NA. J Trop Med Hyg 1986;89:149-55. View abstract.

Schulpis CH, Antoniou C, Michas T, Strarigos J. Phenylalanine plus ultraviolet light: preliminary report of a promising treatment for childhood vitiligo. Pediatr Dermatol 1989;6:332-5. View abstract.

Beckmann H, Athen D, Olteanu M, Zimmer R. DL-phenylalanine versus imipramine: a double-blind controlled study. Arch Psychiatr Nervenkr 1979;227:49-58. View abstract.

Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 1984;59:81-7. View abstract.

Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8. View abstract.

Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-37. View abstract.

Juncos JL, Fabbrini G, Mouradian MM, et al. Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987;44:1003-5. View abstract.

Eriksson T, Granerus AK, Linde A, et al. "On-off" phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38:1245-8. View abstract.

Bornstein RA, Baker GB, Carroll A, et al. Plasma amino acids in attention deficit disorder. Psychiatry Res 1990;33:301-6.. View abstract.

Baker GB, Bornstein RA, Rouget AC, et al. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol Psychiatry 1991;29:15-22.. View abstract.

Wood DR, Reimherr FW, Wender PH. Treatment of attention deficit disorder with DL-phenylalanine. Psychiatry Res 1985;16:21-6.. View abstract.

National Institutes of Health Consensus Development Conference Statement. Phenylketonuria: Screening and Management https://consensus.nih.gov/2000/2000phenylketonuria113html.htm (Accessed 30 October 2015).

Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, DC: National Academy Press, 2002. Available at: http://www.nap.edu/books/0309085373/html/.

Cederbaum S. Phenylketonuria: an update. Curr Opin Pediatr 2002;14:702-6. View abstract.

Wilson CJ, Van Wyk KG, Leonard JV, Clayton PT. Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia. J Inherit Metab Dis. 2000;23:677-83. View abstract.

Cejudo-Ferragud, E., Nacher, A., Polache, A., Cercos-Fortea, T., Merino, M., and Casabo, V. G. Evidence of competitive inhibition for the intestinal absorption of baclofen by phenylalanine. Int J of Pharm (Amsterdam) 1996;132:63-69.

Jukic T, Rojc B, Boben-Bardutzky D, Hafner M, Ihan A. The use of a food supplementation with D-phenylalanine, L-glutamine and L-5-hydroxytriptophan in the alleviation of alcohol withdrawal symptoms. Coll Antropol 2011;35:1225-30. View abstract.

Rucklidge, J. J., Johnstone, J., and Kaplan, B. J. Nutrient supplementation approaches in the treatment of ADHD. Expert.Rev.Neurother. 2009;9(4):461-476. View abstract.

Camacho, F. and Mazuecos, J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. Arch Dermatol 1999;135(2):216-217. View abstract.

Fischer, E., Heller, B., Nachon, M., and Spatz, H. Therapy of depression by phenylalanine. Preliminary note. Arzneimittelforschung. 1975;25(1):132. View abstract.

Wade, D. T., Young, C. A., Chaudhuri, K. R., and Davidson, D. L. A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. J Neurol.Neurosurg.Psychiatry 2002;73(3):246-249. View abstract.

Camacho, F. and Mazuecos, J. Oral and topical L-phenylalanine, clobetasol propionate, and UVA/sunlight--a new study for the treatment of vitiligo. J Drugs Dermatol 2002;1(2):127-131. View abstract.

ten Hoedt, A. E., de Sonneville, L. M., Francois, B., ter Horst, N. M., Janssen, M. C., Rubio-Gozalbo, M. E., Wijburg, F. A., Hollak, C. E., and Bosch, A. M. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit.Metab Dis. 2011;34(1):165-171. View abstract.

Beckmann, H., Strauss, M. A., and Ludolph, E. Dl-phenylalanine in depressed patients: an open study. J.Neural Transm. 1977;41(2-3):123-134. View abstract.

Beckmann, H. and Ludolph, E. [DL-phenylalanine as an antidepressant. Open study (author's transl)]. Arzneimittelforschung. 1978;28(8):1283-1284. View abstract.

Sabelli, H. C., Fawcett, J., Gusovsky, F., Javaid, J. I., Wynn, P., Edwards, J., Jeffriess, H., and Kravitz, H. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. J Clin Psychiatry 1986;47(2):66-70. View abstract.

Cotzias, G. C., Van Woert, M. H., and Schiffer, L. M. Aromatic amino acids and modification of parkinsonism. N Engl.J Med 2-16-1967;276(7):374-379. View abstract.

Kravitz, H. M., Sabelli, H. C., and Fawcett, J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. J Am Osteopath.Assoc 1984;84(1 Suppl):119-123. View abstract.

Mann, J., Peselow, E. D., Snyderman, S., and Gershon, S. D-phenylalanine in endogenous depression. Am.J.Psychiatry 1980;137(12):1611-1612. View abstract.

Hogewind-Schoonenboom JE, Zhu L, Zhu L, et al. Phenylalanine requirements of enterally fed term and preterm infants. Am J Clin Nutr 2015;101(6):1155-62. View abstract.

Katoulis AC, Alevizou A, Bozi E, et al. A randomized, double-blind, vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines. Clin Exp Dermatol 2010;35(5):473-6. View abstract.

Pohle-Krauza RJ, Navia JL, Madore EY, et al. Effects of L-phenylalanine on energy intake in overweight and obese women: interactions with dietary restraint status. Appetite 2008;51(1):111-9. View abstract.

Gorissen SHM, Trommelen J, Kouw IWK, et al. Protein type, protein dose, and age modulate dietary protein digestion and phenylalanine absorption kinetics and plasma phenylalanine availability in humans. J Nutr. 2020 Aug 1;150(8):2041-2050. View abstract.

Amin A, Frampton J, Liu Z, et al. Differential effects of L- and D-phenylalanine on pancreatic and gastrointestinal hormone release in humans: A randomized crossover study. Diabetes Obes Metab. 2021 Jan;23(1):147-157. View abstract.

Fitzgerald PCE, Manoliu B, Herbillon B, Steinert RE, Horowitz M, Feinle-Bisset C. Effects of L-phenylalanine on energy intake and glycaemia-impacts on appetite perceptions, gastrointestinal hormones and gastric emptying in healthy males. Nutrients. 2020 Jun 16;12(6):1788. View abstract.